In recent years, the emergence of immune checkpoint inhibitors (ICIs), including programmed death ligand 1 (PD-L1) inhibitors and programmed death receptor 1 (PD-1) inhibitors, has changed the survival outcome of patients with aggressive extensive SCLC [5]. The gene discussed is CD274; the disease is small cell lung carcinoma.